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Streptococcus pneumoniae, one of the most common gram-positive pathogens to colonize the human upper respiratory tract, is
responsible for many severe infections, including meningitis and bacteremia. A 23-valent pneumococcal vaccine is available to
protect against the 23 S. pneumoniae serotypes responsible for 90% of reported bacteremic infections. Unfortunately, current
S. pneumoniae serotype testing requires a large panel of expensive antisera, assay results may be subjective, and serotype cross-
reactions are common. For this study, we designed an oligonucleotide-based DNA microarray to identify glycosyltransferase
gene sequences speciﬁc to each vaccine-related serotype. Out of 56 isolates representing diﬀerent serotypes, only one isolate,
representing serotype 23A, was not detected correctly as it could not be distinguished from serotype 23F. Our data suggest that the
microarray provides a more cost-eﬀective and reliable way of monitoring pneumococcal capsular types.
1.Introduction
Streptococcus pneumoniae is an important cause of bac-
teremia, community-acquired bacterial pneumonia, and
meningitis, especially among young children and older
adults [1–3]. Capsular polysaccharide is the primary S.
pneumoniae virulence factor and encapsulated pneumococci
are responsible for more diseases than unencapsulated
strains [4]. After comparing the diﬀerences in capsular
polysaccharides composition, S. pneumoniae can be divided
into more than 90 serotypes [5] and the 23 serotypes
responsible for 90% of disease cases [6] are represented in
a 23-valent pneumococcal vaccine. Pneumococcal serogroup
and serotype identiﬁcation is currently performed by using
large panels of expensive antisera by various methods,
including the capsular swelling (Quellung) reaction, latex
agglutination, and coagglutination. Cross-reactions between
serotypes and discrepancies between methods can occur
and some strains are nonserotypable. On the other hand,
molecular typing has the potential to improve discrimi-
nation and provide additional information. S. pneumoniae
capsule production is predominantly controlled by capsular
polysaccharide synthesis (cps) gene clusters [7, 8], which are
responsible for each serotype-speciﬁc polysaccharide. The
Sanger Institute has sequenced the cps gene clusters of 90
S. pneumoniae serotypes and predicted the general function
of 1,973 of the 1,999 gene products [9, 10]. S. pneumoniae
capsular polysaccharides represent a diverse group of poly-
mers with distinct sugar compositions and linkages[10].The
key enzymes to link each serotype-speciﬁc sugar component
are glycosyltransferases (GTs) [11], which transfer the sugar
moiety from an activated nucleotide sugar to an acceptor
to generate a serotype-speciﬁc capsular polysaccharide. After
discovering that S. pneumoniae GT genes are highly variable
and contain serotype- or serogroup-speciﬁc regions, we
used GT sequences as probes in an oligonucleotide-based
microarray to identify 23-valent pneumococcal vaccine and
closelyrelatedS.pneumoniaeserotypes.Ourdatasuggestthat2 Journal of Biomedicine and Biotechnology
the microarray provides a more cost-eﬀective and reliable
way of monitoring serotype distribution.
2.Materialsand Methods
2.1. Bacterial Strains, Growth Conditions, Immunological
Serotyping, and Genomic DNA Extraction. S. pneumoniae
strains representing various serotypes were obtained from
the American Type Culture Collection, the Statens Serum
Institute, and clinical isolates (Table 1). Each strain was
cultivated on brain-heart infusion broth (Eiken, Tokyo,
Japan) supplemented with 0.3% yeast extract (Becton Dick-
inson, Boston, MA) (BHI-Y) for 24h at 37◦Ci n5 %C O 2.
Conventional serotyping was performed for clinical isolates
obtained in Japan by slide agglutination (Denka Seiken,
Tokyo, Japan) or quellung reaction (Statens Serum Institute,
Copenhagen, Denmark).
Genomic DNA was extracted using a Wizard Genomic
DNA puriﬁcation kit (Promega, Madison, WI).
2.2. DNA Array Preparation. Oligonucleotide probes were
synthesized and spotted on a glass slide at Nihon Gaishi
(Nagoya, Japan). The slide was stirred in a beaker ﬁlled with
2 × SSC/0.2%SDSfor15min, transferred to asecond beaker
ﬁlled with 2 × SSC/0.2% SDS to incubate for 5min at 95◦C,
rinsed three times with dH2O, and centrifuged at 900rpm
for3min at 25◦Cin ahorizontal microtiterplaterotorbefore
being covered with a plastic seal.
2.3. Chromosomal DNA Labeling. 500ng of genomic DNA
was suspended in 21µLd H 2Oa n d2 0µLo f2 . 5 ×Random
Primer Solution (Invitrogen, Carlsbad, CA), heated to 95◦C
f o r5 m i n ,a n dc h i l l e do ni c ef o r3 m i n .T h eD N Aw a s
labelled in a reaction including5µL of 10XdCTP Nucleotide
Mix (Invitrogen, Carlsbad, CA), 5µLC y 3o rC y 5 - d C T P
(GE Healthcare, Buckinghamshire, UK), and 1µLo fE x o -
Klenow Fragment (Invitrogen, Carlsbad, CA ). After a 2-
hour incubation at 37◦C, 5µL of sodium acetate, 125µLo f
ethanol and 1µL of glycogen was added to 25µLo fC y 3a n d
Cy5labeled DNA,which was puriﬁed previously by QIAprep
Spin Miniprep Kit (250) (Qiagen, Tokyo, Japan). Following
a 30-minute incubation at −80◦C in the dark, the probe
mixturewascentrifugedfor30minat14,000rpmat4◦C.The
supernatant was removed and the probe was air-dried for
5min in the dark. The probe mixture was diluted in 70µL
of the hybridization buﬀer (25% formamide, 0.1% SDS, 6
× SSPE), incubated for 30min at room temperature in the
dark, heated for 8min at 75◦C, and incubated for 30min at
42◦C.
2.4. Probe Hybridization and Microarray Signal Detection.
Prewarmed probe mixture was applied to the prepared
microarray slide, placed in a hybridization chamber and
incubated for 20h at 42◦C. After hybridization, the plastic
seal was removed and the slide was washed with 1 ×
SSC/0.1% SDS solution for 3min, 0.05 × SSC for 3min,
and 95% ethanol for 90s at room temperature. The washed
microarray slide was dried by centrifugation and scanned
Table 1: Test strains.
Serotype Strain designation Serotype Strain designation
1 ATCC6301a 14 D59b
2 ATCC6302a 15F ATCC6315a
3 D36b 15A ATCC6330a
4 JHK27b 15B ATCC10354a
5 ATCC6305a 15C SSI15C/2c
6A MSC1943b 17F ATCC6317a
6B MSC1047b 17A SSI17A/2c
7F ATCC10351a 18F ATCC6318a
7A ATCC6307a 18A ATCC10344a
7B ATCC10348a 18B ATCC10355a
7C ATCC10350a 18C ATCC10356a
8 ATCC6308a 19F D33b
9A ATCC8333a 19A D4b
9V KD10-11b 19B ATCC10358a
9L ATCC10349a 19C ATCC10359a
9N KD01-26b 20 ATCC6320a
10F ATCC6310a 22F KD01-23b
10A ATCC8334a 22A ATCC10363a
10B SSI10B/2c 23F KD11-15b
10C SSI10C/2c 23A KD12-06b
11F ATCC6311a 23B ATCC10364a
11A SSI11A/2c 33F ATCC10370a
11B SSI11B/2c 33A ATCC8340a
11C ATCC10353a 33B ATCC10342a
11D SSI11D/1c 33C ATCC8339a
12F ATCC6312a 33D SSI33D/2c
12A SSI12A/5c 44 SSI44/3c
12B SSI12B/1c 46 SSI46/2c
Explanatory notes: Serotypes represented in bold letter are those included in
23-valent pneumococcal vaccine.
aAmerican Type Culture Collection.
bClinical isolate obtained from Japan.
cStatens Serum Institute.
using the DNA Microarray Scanner (Agilent, Santa Clara,
CA).
2.5. Data Analysis. The signal and background intensities of
eachspotwerequantiﬁedusingGenePixPro6.0softwareand
the average was calculated with Microsoft Excel software.
3.Results
3.1. Target Gene Selection and Microarray Construction. In
this study, we designed a DNA microarray to identify the 23
S. pneumoniae serotypes included in the 23-valent pneumo-
coccal vaccine, using GT genes in cpslocus.We comparedthe
GT sequences of the 23-valent vaccine serotypes with other
S. pneumoniae serotypes and found that these 23 serotypes
were indistinguishable from 14 nonvaccine serotypes.
Therefore, 37 serotypes, 23-valent vaccine serotypes and
14 closely related serotypes, were divided into 23 groups
and each group had one to six GT genes in their cps locusJournal of Biomedicine and Biotechnology 3
Table 2: Twenty-three groups distinguished in this study and targeted glycosyltransferase genes.
Group
name
Targeted GT genes in cps locus (probe numbera)
1 wchB (1,2,3) wchD (4,5,6)





4 wciJ (22,23,24) wciK (25,26,27) wciL(28,29,30)
5 wciJ (31,23,24) whaC(32,33,34) whaD
(35,36,37)
6A/6B wciN (38,39,40) wciP (41,42,43)






8 wciR (59,60,61) wciR (62,63,64) wciS (65,66,67) wciT
(68,69,70)
9A/9V wchO (71,72,73,74) wcjA (75,76,77) wcjB (78,84,85) WcjC
(81,82,83)
9L/9N wchO (71,72,73,74) wcjA (75,76,77) wcjB (78,79,80) wcjC
(81,82,83)









































19F wchO (167,72,168,169) wchQ
(171,172,173)
19A wchO (71,170,73,74) wchQ
(171,172,173)





























Explanatory notes: aProbes containing 60-bp oligonucleotides were designed and named as 1, 2, 3 etc from Group 1. The name of each GT gene (wchB etc)
was derived from the Sanger Institute.
(Table 2). The 60-bp oligonucleotide probes contained the
variable middle region of each open reading frame and were
designed from published sequences at the Sanger Institute
(http://www.sanger.ac.uk/Projects/S pneumoniae/CPS/)a n d
Genbank websites. In most cases, the designed probes were
gene speciﬁc, although some probes included sequences
frommorethanonegene.Eachserotypegroupwasidentiﬁed
using 3 to 18 probes (Table 2) and a total of 222 probes
were designed to target 23 groups (Table 3). 26 positive
control probes were designed to hybridize S. pneumoniae
housekeeping genes and 16S rDNA. In addition, 26 negative
control probes were designed to detect housekeeping genes
of other bacterial respiratory pathogens, including Klebsiella
pneumoniae, Staphylococcus aureus, Legionella pneumophila,
Chlamydophila pneumoniae, Mycoplasma pneumoniae, Pseu-
domonas aeruginosa,a n dStreptococcuspyogenes.As c h e m a t i c4 Journal of Biomedicine and Biotechnology




gene Speciﬁcity Probe sequence (5 –3 )
1 wchB Serotype1 ATAAGATTATTGAGAAAATATAGACCGGATGTAGTCTTGACATATACC-
GTGAAACCAAAT
2 wchB Serotype1 TTTATTGGTAGGATATTAAAAGAAAAAGGTATAGATACTTATCTGGCTGCT-
GCCCAAATT
3 wchB Serotype1 GAAAATGAAAAACGAAAAGAGATGGGACTTCAAGGGAGAATGTATATA-
GAGCAATATTTT
4 wchD Serotype1 TTATTGAAGGAATGATTGATAGCGACTTAATAGTTGTTCGTATTCCGTCTA-
TAATTGGAT
5 wchD Serotype1 GCCATAGATTTGTATTGGAAGCAATGAAGAGATTAGAAATACAAGGTA-
TTTTGTTGGATT














9 wchF Serotype2 TTATTGAAGCAGTGGAGCAATTTGATGAGAACGCCATTTCTGAACTAG-
ATAAAAAATCTA
10 wchG Serotype2 GCAATACCAAGAAAAATACCCTAAAAAAATTAAGGTTATCACAGATTCCTC-
TGTTATAGG
11 wchG Serotype2 TAGAAGTTTAAACAATCTGTTAGATTTGAATAGTAATGCAGTAGCTATGCA-
TGATTGGTG
12 wchG Serotype2 TTATCAGAATTCTCTAAGTAATGAGGAGACAGATATTATTCGTGAATTTAT-
CAGCATTCC
13 wchH Serotype2 TAGAAACCAGACAATTTTTTATCGGATAAAAGCTTCTTTGGGGAATACTCT-
AAAAAACG
14 wchH Serotype2 CGTATTCCAGAAAAGTTACCTGATACCTATAATGTGTTGATTAATCCTGAA-
AGAGAAAAA
15 wchH Serotype2 CTTTGTTGGAACTCTCAAATGGTCAGAATACTATAGTTGTAGAAGAGTTAT-
CAGAAATAT
16 wchI Serotype2 CATTTTACCAGAACATGGAAATGTGGAAGATGAGCTTGTAAACAAAGG-
AATTAAATACTA
17 wchI Serotype2 TGATTTAGTTAGAGCGATAGCTAATCTTCCTGAGAGATATAAACAGATGTT-
TAAAGTTGA
18 wchI Serotype2 TACAAAAGAGATAATTTCTACAGGAGAAACAGGATATCTGTATGAACC-
AGGAGATTATAT
19 wchE Serotype3 TATAAGTCCTACAGTTGTAGTGTAAGTGATGAGAAGTTATTTAGTTCTGTA-
ATTATCCCT
















25 wciK Serotype4 GGTTCAGAAACAATTGGTGAAAAATTCTTTAATGAATATCGTTTCTTCAGA-
CGGCTATAA
26 wciK Serotype4 TCGATTTCAGTTGAATTTTATAGGTACTAATGCAGGAGAATTAAGGGAATT-





gene Speciﬁcity Probe sequence (5 –3 )
27 wciK Serotype4 GTGAAGATACTTATATGGAAAAAGTGTCAATAGAGAATGGTTTTGGTT-
TCGTTTTACCTA
28 wciL Serotype4 AAAAGCCTCTACATCAGTTTCTCTCTCTTGCTAGAATAATAAAGAAAGGAG-
ATTATGATA
29 wciL Serotype4 AGAACTCATTTTAATCAAACCAAATGTTATTTTACTCCTAGTTGGTAATGG-
TGAGGATGA
30 wciL Serotype4 AAAAACATTAGTTACTTACCTATCAACGAAGAGTCTGTGTTGCTATGGAAA-
GATAAAGTA
31 wciJ Serotype5 TTACATAGGATATTAAATTATTTTAGTTTTGCTATCAGTTCCTCGATAGGG-
GTTCTACTG
32 whaC Serotype5 TTTCTGACTCTCACAAGTATGATGGATTGGTATTACCAAAGAAAAATACAG-
TTCGCAATT
33 whaC Serotype5 TATATCCCGAACCTCAACTTTTGAACCTTTTAACGAGAAATATCATATCCG-
TCAGATTAT
34 whaC Serotype5 GAAGACTAAACTTCAGCGTGAATTGAAACTAGAAGAAGCACGCTATAA-
AGGAAATAGATT
35 whaD Serotype5 AAGACGGCAGTACGCTATTTCTGTTGATGGTATAATAAATCATAGTAATAT-
CTCACTTAA
36 whaD Serotype5 GTTTTCACAAGATATAGTATTCGAAAATCTGAGAAAAATCTGCTTTTTGTG-
GGACAGTTT


























44 wchF Serotype7F, 7A ATACAATACTATGTTGCTTGTATGCGTGAAAATTCAGCTAAATCTGGCATC-
ATGGATGAT




















50 wcwF Serotype7F, 7A AAATATGAAGTTATTCTAGTAAATGATGGCAGTACAGATGCTTCACCCAAT-
ATTTGTGAA
51 wcwF Serotype7F, 7A TATTTTATTGGGAATGATGCGGCTATTACCAAACAGTGGTCTGAAAAA-
AAAATTAGTGAT
52 wcwF Serotype7F, 7A ATGAAATTGTATGAAGAAAATCAGGAAGACACTCAACTTTTTAGGTTGATA-





gene Speciﬁcity Probe sequence (5 –3 )
53 wcwG Serotype7F, 7A AAAACGATTACCCGGATTTTTATTCCATAATTGGTGGTTAGAAGAATGGTC-
TAGAAAATT
54 wcwG Serotype7F, 7A GGTGCAGATAAAGGAAGATTGCCAAAATTAAAAAGCTTAGCTAAGCAG-
ATAGTTTTAAAT
55 wcwG Serotype7F, 7A ATAAAAAGGGACAGGATGGTCTAACCCTTAGAGCAATGGAATCCATTT-
TTTATAAAAAAA
56 wcwH Serotype7F, 7A GGAACAGAGTTACTAAGAATTGTAAAATCAAATCAATTGTAGGCAATA-
TACGTGGCAAAA
57 wcwH Serotype7F, 7A ATTTGCTAAATCCTATAGAGAAACGAAACCCATTTCATCTAGGTATGTTAT-
ATCATGAAG
58 wcwH Serotype7F, 7A TATTTGAATATGCAATTGATGGCGAGAATGCACTTTTATCTCCGATAAAAG-
ATAGTGTTA
59 wciO Serotype8 AACTAATGAAGCTTGAACCGATTATGAGACAACAAGACAGCTATTTAA-
TCACAGAATATA
60 wciO Serotype8 AAATCACTTTATATACTGTTAAGAATACGCCCAAAAGTAGTTATCTGTACA-
GGTGTTCTT
61 wciO Serotype8 TTTATATTGAATCTTTTGCAAAAGTGACCACTCCTACTTTAACAGGTAGAA-
TACTATACC
62 wciR Serotype8 AAAATAGATCAACTTATTGAATTAGAAGTGATAAAGGAAGAGGTGTTT-
GCTCAGATTGGA
63 wciR Serotype8 TAAAGCTTTGAAATTAAGAAAAAAAATTATAGCGGTTCCACGATTAGA-
GCAGTTTGGAGA
64 wciR Serotype8 ATGCTTTGATATAGAGCAGTTAGGAACTGTTTATCAAAAAGCTCAGACTTT-
TACAACAAA
65 wciS Serotype8 TTTATTGATGGCTCTCTTGTAACACGGTTAACCTATTCTAGTTATGCTCTT-
CTTAAATTT
66 wciS Serotype8 AACAACTTTCTTTTTTTAGGAAGGATGGGCAAAAGAAAAGGAGCCTAT-
GATTTAATAGAT
67 wciS Serotype8 AGGATAATGGCTGGTTAATTCAACCGGGTGATATTTCTCAGTTATCTAATA-
TTATTTTAG
68 wciT Serotype8 ATGGAATGAGGATAATTTTGATTTATCAGATTCACAATTTGCGAAGTCTGC-
ATATGAATC
69 wciT Serotype8 GGTGCAATATTATGAGCAAGCAAGTTTTGATATCAATCATTTGGTAACTGT-
CAATACAAT





























































































































































































































































































126 wchK Serotype14 TAAAAATCCAATAATTGTTCCGCGGCTAAAAAAATTTGGTGAGCATGTAAA-
TGATCACCA


















132 wchM Serotype14 AATAGAAAGTATTTTGAATCAAACGTATGATAACCTTGAGGTTCTATTAGT-
CGATGATGG
133 wchM Serotype14 AATAGAAAGTATTTTGAATCAAACGTATGATAACCTTGAGGTTCTATTAGT-
CGATGATGG








136 wchN Serotype14 TATGCGAGAAAACTACTCTGGGAGTATTGGCGTAGAAAAAATAGTTTA-
TGCAATTATTTT








































































150 wciP Serotype17F GAAGAAAAAGATAGACGGATTAAATTGATTGAAAACATATCGGAATAT-
CATGGAGCCTAT
151 wciP Serotype17F GTATACCAATCCTATCTCAACTTTTATGGCTCATAAGGTTTATGGATGTAA-
TACGTTATT
152 wciP Serotype17F ATCTTAAAACGTATCTCGAAAATTGATGAATTAGCTAAAGATCATGCCTTG-
ACTTACAAG
153 wcrV Serotype17F TCGACAGATAGTAGCAAACAGATAATTAACGAGTATCTTAATGCAGAC-
AGTAGATTTAAA
154 wcrV Serotype17F CATGCAAAACTTAAGTTGTTCTGTCAGAATTTTAAGTTAGTGAGGAAA-
CAGATTTTTAGG






















































































174 wciB Serotype20 ATACTGGGGAAAACATTTCCCAGTTAAACCCTTATTACTGTGAATTAACAG-
GTTTATATT
175 wciB Serotype20 AAAAAGGAAATATTATATTGAAACTCTATGTTCTCATTATGCACACACGCT-
AGATGCTAG
176 wciB Serotype20 AATGGCTGTTTCCGATTTTAGATTGTATGTTTGATCAGATTAATCTTTCAG-
AGTTAACTG
177 whaJ Serotype20 TTTCTCAAAAATTAGCGACCGAAAACTCAAATATACGAGTCTTGAAATCAG-
ATAAAGGAA
178 whaJ Serotype20 GATTGATGAGTACGGTTTGAAGTTTAATACGAATTTGAGAGTTTCAGA-
AGATAGTGATTT
179 whaJ Serotype20 CTATGTTTTTTGAGCCTATACAAAATCTATCTGTATCTAGTGTTAGCAATT-
TATCGCTAG
180 wciL Serotype20 GATACGTTATTATTGGGAAATGTATAGATTCTTCAAAGAATATGCATCTGA-
TTATCAGGC
181 wciL Serotype20 TATACATTAGACAATAAATTTGTGCTAGGTCATGTAGGACGTTTGCATTTT-
CAGAAGAAT
182 wciL Serotype20 GACACTACTCTCAGAAGAAGGTGTACCAAAGGAAGTAAAAATCAATGA-
TAATACTTTTTT
183 wcwK Serotype20 AAACAAGATATAGAGATATGGATTTGTTTCAATATTGGTTTCGAGCGG-
TAGAAAAACATG
184 wcwK Serotype20 AATCTATTTAGCATTTTTTATTCAGGGATTATTGGTTATCATGATGCTCAT-
GTCGCTATG
185 wcwK Serotype20 GTGAATATGTGCCTCTGGCTTATTCAGGTAAAATTGAATCTATTATTCACA-
AACAAAAGA
186 wciD Serotype20 TGGCTCAGAAACTGGAAAAAGAGTATTCTGGCATAGTTAGTATAATTG-
ATAAAGAAAATG
187 wciD Serotype20 CATAAAAATTGATGAGAATATGTTCTACGTTGACATGGAGTATATTGTTTT-
TCCAACTCC
188 wciD Serotype20 GAGACAATTGCTAGATGTGTTACTATTATGACAAATGTTTGTCTATCAATG-





gene Speciﬁcity Probe sequence (5 –3 )
189 whaF Serotype20 ACTTTAATACAAAAAACTGAATTTCCTAAATTTATCTGGACTATGTGGTGG-
CAAGGAGAA
190 whaF Serotype20 ATTTGGTTAGATTCAACGATGTATGTCCATCCAGATTTCCCTATTGAAATA-
TTAGAAAGA

































































































































































































































































































































267 MP dnaJ Mycoplasma
pneumoniae
TTGCGCAAGCTCAAGGAATTTATTAAACCTAATCAAGAGGTAAAACAATAT-





gene Speciﬁcity Probe sequence (5 –3 )




























diagram of the probe positions on the microarray is shown
in Figure 1(a).
3.2. Evaluation of the Microarray. A total of 274 oligonu-
cleotide probes were used in this microarray, including
positive and negative controls and GT gene-speciﬁc probes.
The microarray probes were tested using 36 pneumococcal
isolates from 23 vaccine-associated serotypes and 19 addi-
tional pneumococcal isolates belonging to other serotypes
(Table 1). Figure 1(b) shows the examples of scanned pic-
tures of 6 strains representing diﬀerent serotypes. Examples
of the same serotype were tested repeatedly and shown to
have an identical signal pattern, for example, 5 times for
serotype 3 (data not shown). Of 23 strains representing
23-valent vaccine serotype, 18 strains hybridized to all the
speciﬁc set of probes, and four strains hybridized to almost
allthespeciﬁcsetofprobes(Table 4).Thestrain representing
serotype22Fmayactuallybelongtoserotypegroup22F/22A,
since this sample failed to hybridize speciﬁcally to wchF and
wcwA probes but hybridized to the rest of group 22F/22A
speciﬁc probes. Ofthe13strains representing the 23vaccine-
related serotypes, only 1 isolate (serotype 46), failed to
hybridize to a speciﬁc probe while the other 12 strains
hybridized perfectly. Of the 20 nonvaccine serotypes, 19
strains either hybridized partially to GT-speciﬁc probes or
did not hybridize to any probes. One strain, representing
serotype 23A, hybridized to most of the 23F-speciﬁc probe;
thus, 23A may be indistinguishable from 23F using GT gene
sequences.
4.Discussion
In order to develop a more eﬀective S. pneumoniae vaccine,
simple detection methods are required to serotype large
numbers of clinical isolates. Conventional serotyping meth-
ods using large panels of antisera are labourious and require
technical expertise. Our microarray method can determine
serotype of a strain at one time and needs no expertise.
In addition, the microarray method described here has the
potential to be automated. To our knowledge, our report
describes the ﬁrst microarray to utilize GT genes to predict
serotype of any bacteria.
Several molecular typing methods have been developed
based on serotype-speciﬁc sequences [12–21]. Wang et al.
[21]describedmicroarray methodusingwzyandcapAgenes.
Our approach is diﬀerent in that GT genes were selected as
serotype-speciﬁc genes. Since GTs catalyze the transfer of the
sugar moiety to an acceptor and generate a serotype-speciﬁc
capsular polysaccharide, detecting GT genes can directly
reﬂect polysaccharide structure. We discovered considerable
variability within S. pneumoniae GT genes, which provides
groundworkforfutureinvestigationsintonewS.pneumoniae
capsular types. Our method using GT genes can not only
discriminate serotypes but can give information of the
capsular polysaccharide structure.
The DNA microarray described here accurately detects
the majority of S. pneumoniae serotypes and serogroups
included in the 23-valent vaccine and in the 7, 9, 11,
13-valent conjugate vaccines, which will permit serotype
surveillance before and after vaccination. Since 1983, the
23-valent pneumococcal vaccine has been administered to
persons in the United States aged >2y e a r sw i t hc e r t a i n
underlying medical conditions or aged >65 years. In 2000,
t h em o r ee ﬀective PCV7, 7-valent pneumococcal conjugate
vaccine, which protects against serotypes 4, 6B, 9V, 14, 18C,
19F, and 23F was approved for administration [22]. As a
result of PCV7, antibiotic-resistant invasive pneumococcal
infections have decreased dramatically in young children
and older persons [23]; however, an increase in disease
associated with serotypes not included in the PCV7 vaccine,
has been observed [24, 25]. To address serotype vaccine
coverage, the Advisory Committee on Immunization Prac-
tices (ACIP) issued recommendations in February 2010 for
a newly licensed 13-valent pneumococcal conjugate vaccine
(PCV13), which contains the seven serotypes in PCV7 (4,
6B, 9V, 14, 18C, 19F, and 23F) and six additional serotypes
( 1 ,3 ,5 ,6 A ,7 F ,a n d1 9 A )[ 26]. Taken together, our DNA16 Journal of Biomedicine and Biotechnology
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Serotype 3 (strain ID: D36) Serotype 11A (strain ID: SSI 11A/2)
Strain 19F (strain ID: D33)
Strain 22A (strain ID: ATCC10363) Serotype 22F (strain ID: KD01–23)
Serotype 9V (strain ID: KD10-11)
(b)
Figure 1: (a) Microarray oligonucleotide probes layout. Oligonucleotides 1 to 222 are provided in Tables 2 and 3. P represents S.
pneumoniae housekeeping genes and 16S rDNA positive control oligonucleotides. N indicates negative control oligonucleotides designed
from housekeeping genes of other bacterial species. E denotes empty spot. (b) Scanned microarray images of S. pneumoniae genomic DNA
hybridized with 6 samples (serotype 3, 9V, 11A, 19F, 22F and 22A). The numbers correspond to the spot identiﬁers given in Tables 2 and 3,
and Figure 1(a) P indicates positive spot.Journal of Biomedicine and Biotechnology 17
Table 4: Microarray results of each strain.





1 ATCC6301 1, 2, 3, 4, 5, 6 Perfectly matched 1
2 ATCC6302
7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17,
18
Perfectly matched 2
3 D36 19, 20, 21 Perfectly matched 3
4J H K 2 7 22, 23, 24, 25, 26,
27, 28, 29, 30 Perfectly matched 4
5 ATCC6305 23, 24, 31, 32, 33,
34, 35, 36, 37 Perfectly matched 5
6B MSC1047 38, 39, 41, 42, 43





44, 45, 46, 47, 48,
49, 50, 51, 52, 53,
54, 55, 56, 57, 58
Perfectly matched 7F/7A
8 ATCC6308
59, 60, 61, 62, 63,




71, 72, 73, 74, 75,




71, 72, 73, 74, 75,




86, 87, 88, 89, 90,
91, 92, 93, 94, 95,
96, 97, 98, 99, 100
Perfectly matched 10A
11A SSI11A/2
101, 102, 103, 104,




11, 110, 111, 112,
113, 114, 115, 116,
117, 118, 119, 120,
121, 122, 123, 124
1e x t r ap r o b eo f
group 2 hybridized 12F/12A/12B/44/46
14 D59
101, 125, 126, 127,
128, 129, 130, 131,




125, 128, 131, 135,




144, 145, 146, 147,
148, 149, 150, 151,
152, 153, 154, 155,
156





156, 157, 158, 159,
160, 161, 162, 163,
164, 165, 166
Perfectly matched 18B/18C
19F D33 72, 167, 168,169,
171, 172, 173 Perfectly matched 19F
19A D4 71, 73, 74, 169,
170, 171, 172, 173,
1e x t r ap r o b eo f
group 19F
hybridized
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Table 4: Continued.
Serotype Strain ID Positive probea Microarray result
Assined group
20 ATCC6320
174, 175, 176, 177,
178, 179, 180, 181,
182, 183, 184, 185,
186, 187, 188, 189,
190, 191
Perfectly matched 20
22F KD01-23 7, 8, 44, 195, 196,
197, 198, 199, 200








144, 145, 156, 193,




208, 209, 210, 211,
212, 213, 214, 215,






6A MSC1943 38, 39, 40, 41, 42,
43 Perfectly matched 6A/6B
7A ATCC6307
44, 45, 46, 47, 48,
49, 50, 51, 52, 53,
54, 55, 56, 57, 58
Perfectly matched 7F/7A
9A ATCC8333
71, 72, 73, 74, 75,




71, 72, 73, 74, 75,




101, 102, 103, 104,




110, 111, 112, 113,
114, 115, 116, 117,
118, 119, 120, 121,
122, 123, 124, 274
Perfectly matched 12F/12A/12B/44/46
12B SSI12B/1
110, 111, 112, 113,
114, 115, 116, 117,
118, 119, 120, 121,
122, 123, 124, 274
Perfectly matched 12F/12A/12B/44/46
15C SSI15C/2
125, 128, 131, 135,




156, 157, 158, 159,




7, 48, 49, 192, 193,




208, 209, 210, 211,
212, 213, 214, 215,
216, 217, 218, 219,
220, 221, 222
Perfectly matched 33F/33A/37Journal of Biomedicine and Biotechnology 19
Table 4: Continued.
Serotype Strain ID Positive probea Microarray result
Assined group
44 SSI44/3
110, 111, 112, 113,
114, 115, 116, 117,
118, 119, 120, 121,
122, 123, 124, 274
Perfectly matched 12F/12A/12B/44/46
46 SSI46/2
110, 111, 112, 113,
114, 115, 116, 117,
119, 120, 121, 122,
123, 124, 274







7B ATCC10348 143, 155 Partial
hybridization
Not included in 23
group
7C ATCC10350 none None
hybridization
Not included in 23
group
10F ATCC6310 86, 87, 88 Partial
hybridization
Not included in 23
group
10B SSI10B/2 71, 72, 73, 74, 78,
79, 80, 81, 82, 83
Partial
hybridization
Not included in 23
group




Not included in 23
group




Not included in 23
group
11B SSI11B/2 101 Partial
hybridization
Not included in 23
group
11C ATCC10353 101, 274 Partial
hybridization
Not included in 23
group




Not included in 23
group




Not included in 23
group
17A SSI17A/2 none None
hybridization
Not included in 23
group
18F ATCC6318
144, 145, 156, 157,
158, 159, 162, 163,
164, 165, 166, 193
Partial
hybridization
Not included in 23
group
18A ATCC10344
144, 145, 156, 158,




Not included in 23
group




Not included in 23
group
19C ATCC10359 72,169,171,172 Partial
hybridization
Not included in 23
group
23A KD12-06
144, 146, 156, 201,
202, 203, 204, 205,
206, 207




23B ATCC10364 7, 46, 202, Partial
hybridization
Not included in 23
group
33B ATCC10342 none None
hybridization
Not included in 23
group
33C ATCC8339 none None
hybridization
Not included in 23
group
33D SSI33D/2 49, 57 Partial
hybridization
Not included in 23
group
Explanatory notes: aThe numbers correspond to the spot identiﬁers given in Tables 2, 3,a n dFigure 1(a).20 Journal of Biomedicine and Biotechnology
microarray will be able to monitor serotype prevalence of all
vaccine-related serotypes. However, in examining serotype
replacement in vaccinated population a further study to dis-
tinguish more than 90 serotypes is required and is currently
under investigation. Moreover, further study of the repro-
ducibility of the microarray is needed.
5.Conclusion
We developed a S. pneumoniae DNA microarray that iden-
tiﬁes GT gene polymorphisms to distinguish capsular types.
We believe that our microarray system is more reliable and
cost-eﬀectiveand will help to surveythe emergence ofnew S.
pneumoniae serotype.
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